Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2019 May 17;19(9):560–569. doi: 10.1016/j.clml.2019.05.001

Table 3.

Results survival analysis

Progression free survival
Diagnosis N Event Median PFS time in months (95%CI) PFS rate at 1 year (95%CI) PFS rate at 3 years (95%CI)
NDMM 13 11 19.61 (5.26 , NA ) 0.62 (0.4 , 0.95 ) 0.28 (0.11 , 0.7 )
PCL 11 11 7.56 (4.7 , NA ) 0.27 (0.1 , 0.72 ) 0.09 (0.01 , 0.59 )
RRMM 116 109 4.63 (3.75 , 6.73 ) 0.21 (0.15 , 0.3 ) 0.04 (0.01 , 0.1 )
Overall survival
Diagnosis N Event Median OS time in months (95%CI) OS rate at 1 year (95%CI) OS rate at 3 years (95%CI)
NDMM 13 9 35.41 (18.13 , NA ) 0.83 (0.65 , 1 ) 0.48 (0.26 , 0.88 )
PCL 11 10 16.06 (11.24 , NA ) 0.64 (0.41 , 0.99 ) 0.09 (0.01 , 0.59 )
RRMM 116 87 13.96 (10.91 , 17.74 ) 0.55 (0.47 , 0.65 ) 0.21 (0.14 , 0.31 )

NDMM: newly diagnosed multiple myeloma; PCL: plasma cell leukemia; RRMM: relapsed refractory multiple myeloma, PFS: progression free survival, OS: overall survival.